Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 7/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.36 |
| ▸ | ACP1 | P24666 | 1/20 | 0.34 |
| ▸ | RAD52 | P43351 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9922118 | 0.94 | P2RY12 (0.37) | EPHX2MCHR1P2RY12MAPT | |
| SCHEMBL9922115 | 0.92 | P2RY12 (0.43) | L3MBTL1EPHX2LMNAP2RY12MAPT | |
| SCHEMBL12177251 | 0.89 | HRH3 (0.38) | P2RY12MAPTMET | |
| SCHEMBL9923130 | 0.88 | KMT2A (0.46) | L3MBTL1EPHX2RAB9AP2RY12RAD52 | |
| SCHEMBL14228477 | 0.88 | MET (0.39) | L3MBTL1EPHX2LMNAKDM4EGAA | |
| SCHEMBL12177245 | 0.87 | P2RY12 (0.38) | LMNAGAARAB9AP2RY12MAPT | |
| SCHEMBL9922344 | 0.86 | KMT2A (0.42) | EPHX2LMNAGAAP2RY12MAPT | |
| SCHEMBL12161212 | 0.86 | P2RY12 (0.44) | EPHX2P2RY12MAPT | |
| SCHEMBL9922121 | 0.85 | P2RY12 (0.43) | EPHX2P2RY12MAPT | |
| SCHEMBL12177094 | 0.84 | MET (0.40) | L3MBTL1EPHX2RAB9ARAD52MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622474-B2 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194597-A1 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PIGS, GP6, ASGR1 | L3MBTL1 3635/4885EPHX2 3302/4885LMNA 3577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.